secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001567264-24-000017
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics appoints Thomas Dubin to Board, restores Audit Committee compliance
--------------------------------------------------------------------------------

- Thomas I. H. Dubin appointed as Class I director, expanding Board from 4 to 5 members.
- Dubin will serve on Audit Committee, restoring Nasdaq compliance after Daniel Donovan's resignation.
- Granted options to purchase 50,000 shares at $4.42 per share, vesting in four equal installments.
- Dubin brings deep experience from Alexion Pharmaceuticals (former chief legal officer) and other biotech roles.
- Four of five Board members are now independent per Nasdaq standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000017/0001567264-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000017/intensity-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001567264-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer